<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659022</url>
  </required_header>
  <id_info>
    <org_study_id>SILENT</org_study_id>
    <nct_id>NCT00659022</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth</brief_title>
  <official_title>Accelerated Growth of Synchronous Colorectal Liver Metastases: Effects of Neo-adjuvant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis

      • As well as in animal models as in patients with colorectal cancer resection of the primary
      tumor resulted in increase in vascular density, metabolism and secondary tumor growth of the
      distant metastases. These data strongly suggest an inhibitory effect of the primary tumor on
      the outgrowth of its metastases.

      In this study we investigate whether pre-operative treatment with the anti-angiogenic agent
      bevacizumab and/or chemotherapy before resection of the primary colorectal tumor shifts the
      balance between angiogenic and anti-angiogenic factors in favor of the anti-angiogenic
      factors and results in reduced growth of the liver metastases.

      Eligibility

        -  Histological proven colorectal cancer without signs of bowel obstruction or bleeding

        -  Synchronous liver metastases

        -  WHO performance status 0-1

      Treatment

        -  Arm A: immediate surgery of the primary colorectal tumor, no neoadjuvant therapy

        -  Arm B: neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the
           colorectal primary

        -  Arm C: neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the
           colorectal primary

        -  Arm D: neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery
           of the colorectal primary

      Primary endpoint Difference in response of liver metastases to resection of the primary tumor
      between the experimental groups and the control group, as determined by histopathological
      scoring of vascular density, apoptotic and mitotic index and by measurement of the metabolic
      activity of liver metastases by FDG-PET and SUV measurements.

      Secondary endpoints Toxicity of neo-adjuvant treatment Complications of surgery
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in response of liver metastases between control group and experimental groups determined by histopathological scoring of vascular density,apoptotic and mitotic index</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in response of liver metastases between control group and experimental groups determined by FDG-PET</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of neo-adjuvant treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgery</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immediate surgery of the primary colorectal tumor, no neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immediate surgery (resection of primary colorectal tumor)</intervention_name>
    <description>no neo-adjuvant treatment, immediate surgery</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neo-adjuvant treatment with bevacizumab</intervention_name>
    <description>neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant treatment with capecitabine and oxaliplatin</intervention_name>
    <description>neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin</intervention_name>
    <description>neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary</description>
    <arm_group_label>D</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Xeloda</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological proven primary colorectal cancer and synchronous
             unresectable liver metastases with or without additional extrahepatic disease (primary
             tumor in situ). Unresectable liver metastases defined as too extensive hepatic
             involvement or extrahepatic disease.

          -  Measurable liver metastases on CT scan (RECIST), positive signal of liver metastases
             on FDG-PET scan

          -  Age: 18-80 years

          -  WHO performance scale 0-1

          -  ASA category I or II

          -  Negative pregnancy test in women with childbearing potential

          -  Life expectancy &gt; 12 weeks

          -  Laboratory values obtained ≤ 3 weeks prior to study entry, disease evaluation
             performed ≤ 3 weeks prior to study entry. Adequate bone marrow function (Hb &gt; 6.5
             mmol/L, absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x 109/L), renal
             function (serum creatinine &lt; 1.5 x ULN or creatinine clearance ≥ 50 mL/min (calculated
             according to Cockroft and Gault), liver function (ASAT and ALAT ≤ 3 x upper normal
             limit, serum bilirubin ≤ 2 x upper normal limit)

          -  Written informed consent

        Exclusion Criteria:

          -  Signs of bowel obstruction or bleeding from primary tumor

          -  Prior chemotherapy treatment for advanced disease, prior treatment with
             anti-angiogenic drugs

          -  Resectable liver metastases

          -  Diabetes mellitus

          -  Continuous use of immunosuppressive agents

          -  Pregnancy or lactation

          -  Contra-indications for systemic therapy with bevacizumab (Avastin)/ chemotherapy
             (Xelox)

          -  Concurrent severe or uncontrolled disease (i.e. uncontrolled hypertension, congestive
             heart failure, myocardial infarction &lt; 12 months, chronic active infection)

          -  Sensory neuropathy &gt; grade 1

          -  Serious non-healing wound or ulcer

          -  Patients (M/F) with reproductive potential not implementing adequate contraceptive
             measures

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to start of bevacizumab

          -  Bleeding disorders or coagulopathy or need for full-dose anticoagulation

          -  Signs or symptoms of brain metastases

          -  Cerebrovascular accident or transient ischemic attack within the past 12 months

          -  Impairment of gastrointestinal function or -disease that may significantly impair the
             absorption of oral drugs (i.e. uncontrolled nausea, vomiting, diarrhea, malabsorption
             syndrome, bowel obstruction, or inability to swallow tablets)

          -  Presence of proteinuria at baseline as defined by: patients with &gt; 1 g of protein/24
             hr by a 24-hour urine collection.

          -  Any concomitant disorder preventing the safe administration of study drugs or surgical
             procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Ruers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kees Punt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wim Oyen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Bottenberg, Ma ANP</last_name>
    <phone>+31-20-5122639</phone>
    <email>p.bottenberg@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theo Ruers, PhD</last_name>
    <phone>+31-20-5122538</phone>
    <email>t.ruers@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theo Ruers, PhD</last_name>
      <phone>+31-20-5122538</phone>
      <email>t.ruers@nki.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kees Punt, PhD</last_name>
      <phone>+31-24-3610353</phone>
      <email>C.Punt@onco.umcn.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Gorelik E, Segal S, Feldman M. On the mechanism of tumor &quot;concomitant immunity&quot;. Int J Cancer. 1981 Jun 15;27(6):847-56.</citation>
    <PMID>7287231</PMID>
  </reference>
  <reference>
    <citation>O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315-28.</citation>
    <PMID>7525077</PMID>
  </reference>
  <reference>
    <citation>O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277-85.</citation>
    <PMID>9008168</PMID>
  </reference>
  <reference>
    <citation>Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004 Nov 20;112(4):554-9.</citation>
    <PMID>15382035</PMID>
  </reference>
  <reference>
    <citation>Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer. 2005 Apr 15;103(8):1561-70. Review.</citation>
    <PMID>15754332</PMID>
  </reference>
  <reference>
    <citation>Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004 Oct;4(10):806-13. Review.</citation>
    <PMID>15510161</PMID>
  </reference>
  <reference>
    <citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004 Jun 1;64(11):3731-6.</citation>
    <PMID>15172975</PMID>
  </reference>
  <reference>
    <citation>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005 Jan 7;307(5706):58-62. Review.</citation>
    <PMID>15637262</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>T.J.M Ruers, PhD</name_title>
    <organization>The Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital Amsterdam</organization>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

